Markets
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cassava Sciences (SAVA – Research Report), with a price target of $97.00. The company’s shares closed last Thursday at $35.50.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 32.0% and a 40.5% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Aridis Pharmaceuticals, and Achieve Life Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cassava Sciences with a $89.75 average price target, representing a 154.5% upside. In a report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $110.00 price target.